We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Procalcitonin Test Helps to Rationalize Antibiotic Use

By Biotechdaily staff writers
Posted on 03 Mar 2004
Researchers in Switzerland have developed a test for the blood protein procalcitonin that allows the physician to differentiate between viral and bacterial infections and will reduce the inappropriate use of antibiotics.

In microbial infections and in various forms of severe systemic inflammation, circulating levels of calcitonin precursors (CTpr), including the prohormone procalcitonin (ProCT), increase several-fold to several thousand-fold, and this increase often correlates with the severity of the condition and with mortality. More...
Initially, calcitonin is biosynthesized as ProCT, a precursor which is cleaved enzymatically into free aminoprocalcitonin (N-ProCT) and the conjoined calcitonin:calcitonin-carboxypeptide-I (CT:CCP-I). The latter, in turn, is processed into free CCP-I and immature CT. The thirty-three amino acid immature CT is then amidated to yield the thirty-two amino acid mature CT. All these peptides are found in the serum of healthy people. However, in sepsis, with the exception of mature CT, they are increased to a more or less marked extent.

Investigators at University Hospital (Basel, CH) divided a group of 243 patients into two groups based on procalcitonin levels in the blood. Only those with elevated levels of procalcitonin were treated with antibiotics. More than 97% of patients in both groups made complete recoveries, so withholding of antibiotic did not have a detrimental effect on the outcome of the disease. These findings were published in the February 21, 2004, issue of The Lancet.

Senior author Dr. Beat Müller, a researcher in the department of internal medicine at University Hospital, explained, "Procalcitonin guidance substantially reduced antibiotic use in lower respiratory tract infections. Withholding antimicrobial treatment did not compromise outcome. In view of the current overuse of antimicrobial therapy in often self-limiting acute respiratory tract infections, treatment based on procalcitonin measurement could have important clinical and financial implications.”



Related Links:
University Hospital (Basel)

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automated Urinalysis Solution
UN-9000
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.